Mersana Therapeutics, Inc. MRSN
We take great care to ensure that the data presented and summarized in this overview for Mersana Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRSN
View all-
Nextech Invest Ag12.1MShares$4.34 Million3.22% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$4.08 Million0.76% of portfolio
-
Vr Adviser, LLC New York, NY10.3MShares$3.69 Million2.42% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$3.12 Million3.35% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$3.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.06MShares$2.54 Million0.0% of portfolio
-
Novo Holdings Hellerup, G74.25MShares$1.53 Million0.49% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.43MShares$1.24 Million0.2% of portfolio
-
State Street Corp Boston, MA2.76MShares$995,3620.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.53MShares$912,4000.0% of portfolio
Latest Institutional Activity in MRSN
Top Purchases
Top Sells
About MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at MRSN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Jan 16
2025
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
SELL
Open market or private sale
|
Direct |
8,048
-3.03%
|
$0
$0.58 P/Share
|
|
Jan 16
2025
|
Anna Protopapas Director |
SELL
Open market or private sale
|
Direct |
8,637
-4.89%
|
$0
$0.58 P/Share
|
|
Jan 16
2025
|
Ashish Mandelia VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,554
-5.82%
|
$0
$0.58 P/Share
|
|
Jan 16
2025
|
Brian De Schuytner SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
8,470
-6.52%
|
$0
$0.58 P/Share
|
|
Jan 16
2025
|
Martin H. Huber Jr. President, CEO |
SELL
Open market or private sale
|
Direct |
4,514
-3.54%
|
$0
$0.58 P/Share
|
|
Jan 16
2025
|
Mohan Bala SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,939
-7.94%
|
$0
$0.58 P/Share
|
|
Jan 16
2025
|
Alejandra Carvajal SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,096
-6.11%
|
$0
$0.58 P/Share
|
|
Jan 15
2025
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,791
+3.65%
|
-
|
|
Jan 15
2025
|
Anna Protopapas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+10.74%
|
-
|
|
Jan 15
2025
|
Ashish Mandelia VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,685
+6.87%
|
-
|
|
Jan 15
2025
|
Brian De Schuytner SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,833
+7.62%
|
-
|
|
Jan 15
2025
|
Martin H. Huber Jr. President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,062
+7.99%
|
-
|
|
Jan 15
2025
|
Mohan Bala SVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,583
+16.31%
|
-
|
|
Jan 15
2025
|
Alejandra Carvajal SVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+13.04%
|
-
|
|
Jan 15
2025
|
Ashish Mandelia VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,791
-3.31%
|
$0
$0.63 P/Share
|
|
Jan 15
2025
|
Anna Protopapas Director |
SELL
Open market or private sale
|
Direct |
6,191
-3.83%
|
$0
$0.63 P/Share
|
|
Jan 15
2025
|
Alejandra Carvajal SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
952
-1.33%
|
$0
$0.63 P/Share
|
|
Jan 15
2025
|
Brian De Schuytner SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
2,331
-2.09%
|
$0
$0.63 P/Share
|
|
Jan 15
2025
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
SELL
Open market or private sale
|
Direct |
1,794
-0.72%
|
$0
$0.63 P/Share
|
|
Jan 14
2025
|
Ashish Mandelia VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,783
+8.11%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 618K shares |
|---|
| Other acquisition or disposition | 8.04M shares |
|---|---|
| Open market or private sale | 199K shares |